In parallel to the deeper exploration of the biology of ROS1+ NSCLC, the second goal of this exploratory analysis consists in identifying candidate genes whose dysregulated expression in a ROS1+-specific manner might be considered as novel therapeutic targets or biomarkers. Here, ROS1 is linked to non-small cell lung carcinoma.